Compare Carnival Corp (CCL) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Carnival Corp vs Novartis AG — how do they compare? Carnival Corp trades at $27.73 (market cap $39.71B), while Novartis AG trades at $154.71 (market cap $298.18B). The key difference: Novartis AG is far larger — about 7.5× Carnival Corp's market cap, and Novartis AG pays the higher dividend (3.02%). Which is the better fit depends on your goals.
| CCL | NVS | |
|---|---|---|
Market Cap | $39.71B | $298.18B |
Sector | Consumer Cyclical | Health |
52-Week High | $33.99 | $168.62 |
52-Week Low | $23.89 | $119.31 |
Enterprise Value | $63.63B | $339.50B |
Dividend Yield | 1.55% | 3.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Carnival Corporation (CCL) trades at $28.99, up 0.69% today, with a bullish technical signal from moving averages and strong support at $28. The stock shows robust fundamentals, with revenue growing to $26.62B in 2025 and net income at $2.76B, while recent quarters have beaten EPS estimates. Analysts maintain a buy consensus with a $35.18 price target, and positive news highlights fleet expansion and sustainability initiatives.
The outlook for CCL is positive, driven by record travel demand, cost control, and debt reduction, offering potential upside to the consensus target. Risks include fuel price volatility, economic sensitivity, and high leverage, though improved cash flow and dividend reinstatement support investor confidence.
Novartis (NVS) trades at $156.33, up 1.37% on the day, with a bullish technical signal and strong support near $156. The company reported Q2 2026 earnings that beat expectations, driven by robust oncology drug sales, and reaffirmed full-year guidance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%, while valuation ratios like P/E of 23.61 and P/B of 7.15 reflect premium pricing. Recent news highlights institutional buying and CEO confidence in the growth pipeline.
The outlook for NVS is positive, supported by earnings momentum and a diversified drug portfolio, but risks include generic competition for Entresto and pricing pressures. Analyst consensus is mixed with 24% buy ratings, indicating cautious optimism. Investment appeal hinges on execution of new drug launches and offsetting legacy product declines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Carnival Corp
Carnival is the largest global cruise company, with 91 ships in its fleet in October 2022, with eight of its nine brands set to be fully redeployed by the end of 2022. Its portfolio of brands includes Carnival Cruise Lines, Holland America, Princess Cruises, and Seabourn in North America.
Read more on CCL →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
